- Topic1/3
38k Popularity
20k Popularity
3k Popularity
25k Popularity
17k Popularity
- Pin
- 📢 #Gate Square Writing Contest Phase 3# is officially kicks off!
🎮 This round focuses on: Yooldo Games (ESPORTS)
✍️ Share your unique insights and join promotional interactions. To be eligible for any reward, you must also participate in Gate’s Phase 286 Launchpool, CandyDrop, or Alpha activities!
💡 Content creation + airdrop participation = double points. You could be the grand prize winner!
💰Total prize pool: 4,464 $ESPORTS
🏆 First Prize (1 winner): 964 tokens
🥈 Second Prize (5 winners): 400 tokens each
🥉 Third Prize (10 winners): 150 tokens each
🚀 How to participate:
1️⃣ Publish an
- 📢 Gate Square #TopContentChallenge# is coming! Post high-quality content and win exclusive rewards!
🌟 We will select outstanding posts for exposure, and help elevate your influence!
💡 How to Participate?
1.Add the #TopContentChallenge# tag to your post.
2.Posts must be over 60 characters and receive at least 3 interactions (Likes/Comment/Share).
3.Post may include only the #TopContentChallenge# tag.
🎁 We’ll select 1 top post to win $50 Futures Voucher every Tuesday and Thursday!
📃 High-quality posts will be shared on Gate Square and labeled as [Featured Posts]!
📌 Rewards will be distribu
- 🎉 [Gate 30 Million Milestone] Share Your Gate Moment & Win Exclusive Gifts!
Gate has surpassed 30M users worldwide — not just a number, but a journey we've built together.
Remember the thrill of opening your first account, or the Gate merch that’s been part of your daily life?
📸 Join the #MyGateMoment# campaign!
Share your story on Gate Square, and embrace the next 30 million together!
✅ How to Participate:
1️⃣ Post a photo or video with Gate elements
2️⃣ Add #MyGateMoment# and share your story, wishes, or thoughts
3️⃣ Share your post on Twitter (X) — top 10 views will get extra rewards!
👉
Eli Lilly expects to submit a market application for orforglipron for weight management to global regulators by the end of the year.
Jin10 Data reported on April 18 that Eli Lilly announced positive top-line results from the Phase 3 clinical trial ACHIEVE-1, which evaluated the safety and efficacy of orforglipron compared to placebo in patients with type 2 diabetes whose blood sugar control remained inadequate despite dietary control and exercise. Eli Lilly stated that Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase 3 trial without restrictions on diet or fluid intake. Eli Lilly expects to submit a marketing application for orforglipron for weight management to global regulatory agencies by the end of this year, and anticipates submitting its application for the treatment of type 2 diabetes in 2026.